Nasdaq
$3.07▲ 0.66%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $339.4MShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.2After-hours26.10.03 05:434Ownership#●●●
C4 Therapeutics, Inc.
Insider Anderson Kenneth Carl of C4 Therapeutics, Inc. filed a Form 4 report regarding a change in beneficial ownership of securities as of October 1, 2026. This filing serves as an official notification of the insider's equity transaction to the SEC.…more
$3.07+0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:434Ownership
C4 Therapeutics, Inc.
Insider Donna Roy Grogan of C4 Therapeutics reported a change in beneficial ownership of securities effective October 1, 2026. This filing serves as a standard disclosure of executive equity activity and does not involve material changes to the company's capital structure or financial position.…more
$3.07+0.66%vs prev closeView filingShare - 9.25Pre-market26.09.25 20:048-KKey event
C4 Therapeutics, Inc.
C4 Therapeutics presented new biomarker data from its Phase 1 and 1b clinical trials of cemsidomide for relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting. The data demonstrated coordinated T-cell activation and NK-cell reprogramming in the Phase 1 trial, while the 75µg dose in the Phase 1b trial with elranatamab was declared safe, allowing for further dose escalation.…more
$3.07+0.66%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.25Pre-market26.09.25 20:00#●●●#●●●#●●●
C4 Therapeutics Presents Positive Biomarker Data for Cemsidomide in Multiple Myeloma Trials…more
C4 Therapeutics released new biomarker data from its Phase 1 and 1b trials, demonstrating that cemsidomide effectively activates immune cells in patients with relapsed/refractory multiple myeloma. Following the confirmation of safety in the Phase 1b trial, the company is advancing to further dose escalation and expansion cohorts.…more
$3.07+0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3Pre-market26.09.03 20:00
●●●●●●●● ●●●●● ●●●●●●
C4 Therapeutics will present new biomarker data demonstrating the immunomodulatory effects of its multiple myeloma candidate at an upcoming international meeting. The findings further support the potential of the drug as a combination therapy partner.…more
$3.07+0.66%vs prev close - 8.10After-hours26.08.11 05:01
●●●●●●●● ●●●●● ●●●●●●
C4 테라퓨틱스가 나스닥 상장 규정에 따라 신규 직원에게 16만 2,880주 규모의 주식매수선택권을 부여했습니다. 이는 우수 인재 영입을 위한 통상적인 보상책으로, 회사 운영 및 주가에 미치는 직접적인 영향은 제한적입니다.…more
$3.07+0.66%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report